Patient Area
04
2024
-
09
Recruitment Information CAR-T-19 [Recruiting]
CAR-T-19 (anti-CD19 single-chain antibody chimeric antigen receptor T cell) injection for the treatment of CD19 positive relapsed/refractory B-cell acute lymphoblastic leukemia in patients aged 25 years (inclusive) and below: Phase II clinical study [Recruiting]
Chinese Academy of Medical Sciences Blood Disease Hospital
Beijing Bo Ren Hospital
Beijing Children's Hospital Affiliated to Capital Medical University
Peking University People's Hospital
Children's Hospital Affiliated to Capital Institute of Pediatrics
Henan Provincial Cancer Hospital
Shandong University Qilu Hospital
Anhui Provincial Children's Hospital
Zhengzhou University First Affiliated Hospital
Shanxi Provincial Cancer Hospital
Xuzhou Medical University Affiliated Hospital
Zhejiang University School of Medicine Affiliated Children's Hospital
Nanchang University First Affiliated Hospital
Central South University Xiangya Second Hospital
Sichuan University West China Second Hospital
Harbin Blood Research Institute
Huazhong University of Science and Technology Tongji Medical College Affiliated Union Hospital
If you meet the following criteria:
Understand and voluntarily sign the informed consent form;
Age 25 years (inclusive) or below at screening, regardless of gender;
Bone marrow examination confirms the diagnosis of acute B lymphoblastic leukemia and meets one of the following two conditions:
1. Relapsed B-ALL:
(Relapse within 12 months after first remission; late relapse (≥12 months) after first remission with relapse or no remission after first-line/multiple salvage chemotherapy; experiencing two or more bone marrow relapses; relapse after autologous or allogeneic hematopoietic stem cell transplantation);
2. Refractory B-ALL:
(Patients who have not achieved complete remission after two cycles of standardized induction chemotherapy); tumor cells expressing CD19 detected in bone marrow (BM) or peripheral blood (PB) during the screening period;
Expected survival of at least 12 weeks;
Sufficient venous access (for apheresis) and no other contraindications for blood cell separation;
Then you may meet the inclusion criteria for this study.
Previous Page
Previous Page